Nanoformulated drugs can improve pharmacodynamics and bioavailability while serving also to reduce drug toxicities for antiretroviral (ART) medicines. To this end, our laboratory has applied the principles of nanomedicine to simplify ART regimens and as such reduce toxicities while improving compliance and drug pharmacokinetics. Simple and reliable methods for manufacturing nanoformulated ART (nanoART) are shown. Particles of pure drug are encapsulated by a thin layer of surfactant lipid coating and produced by fractionating larger drug crystals into smaller ones by either wet milling or high-pressure homogenization. In an alternative method free drug is suspended in a droplet of a polymer. Herein, drug is dissolved within a polymer then agitated by ultrasonication until individual nanosized droplets are formed. Dynamic light scattering and microscopic examination characterize the physical properties of the particles (particle size, charge and shape). Their biologic properties (cell uptake and retention, cytotoxicity and antiretroviral efficacy) are determined with human monocyte-derived macrophages (MDM). MDM are derived from human peripheral blood monocytes isolated from leukopacks using centrifugal elutriation for purification. Such blood-borne macrophages may be used as cellular transporters for nanoART distribution to human immunodeficiency virus (HIV) infected organs. We posit that the repackaging of clinically available antiretroviral medications into nanoparticles for HIV-1 treatments may improve compliance and positively affect disease outcomes.
1. Weigh the drug crystals and various surfactants that will be used to make the nanoformulations using an analytical balance and mix them with 10 mM Hepes buffer, pH 7.8 using a T-18 Ultraturrax mixer until completely dispersed. The percent of the drug in the formulation should be between 1 -2%. 2. For continuous milling, make sure that the chiller and the compressor is on. The outlet pressure should be around 100 PSI before starting to mill your sample. 3. Turn on the control unit and rotate the grinding tank so that the grinding media can be loaded in the tank. 4 . Add 50 mL of beads to the grinding chamber using a funnel. Make sure that there are no beads in the threads or anywhere outside the grinding chamber to avoid leaks in the mechanical seal. 5. Make sure that the O-ring is in its place on the milling chamber. Select an appropriate screen mesh size and use the appropriate lid assembly and secure the lids by tightening the nuts. The screen mesh size should be at least half the size of the beads. Use a large screen mesh size to avoid the product from clogging the filter while continuous milling. 6. Lower the grinding chamber to make it horizontal using the knob provided on the top of the chamber and make sure that the product outlet tube empties into the collecting vessel. 7. Add the drug suspension with various amounts of surfactants to the product inlet. The minimum volume of the suspension should be 100 mL.
This will prevent the milling chamber from overheating and also avoid bead contamination due to less wear on parts 8. Start the pump using the control unit. The flow rate can be varied as required for your formulation (~ 50 -150 mL/min). 9. Turn the agitator on and adjust the speed on the control unit. The speed can be increased from 620 rpm to 4320 rpm on a MicroCer. Monitor the temperature using the temperature gauge that is attached on top on the grinding chamber and make sure that there is no overheating. 10. Mill the sample at various speeds and flow rates and take out small aliquots (~1 mL) of the formulation for size and charge measurements using a Diffraction Light Scattering Brookhaven Zetasizer (Table 1 ).
1. Measure 50 mL of dichloromethane into a glass beaker. Measure 6 g of poly (lactic-co-glycolic acid) (PLGA) using the analytical balance, add to the dichloromethane, and mix until complete dissolution is observed. 2. Measure 1.25 g of the drug crystals and add to the dichloromethane/ PLGA solution. Mix to obtain complete dissolution. 3. Make 1% polyvinyl alcohol (PVA) surfactant solution and cool it using an ice bath. Make sure that the surfactant solution is cool before the addition of the organic solution that contains the dissolved drug. 4. Pour the drug solution into the 1% PVA surfactant solution and start the ultrasonicator at 50% amplitude. Make sure that the surfactant solution is placed in an ice bath. The amplitude of the sonicator can be reduced to ~ 30% amplitude for smaller batches of samples. Sonicate the sample for 10 minutes. 5. Take out a small aliquot (~ 1 mL) for particle size analysis (Table 1) . If the size of the particles is greater than 1.5 μm, sonicate the sample at 2-minute intervals up to a maximum of 16 minutes total. Observe the samples under the microscope at 20x and document observations ( Figure 1A ). 6. Use a stir plate to create an adequate vortex for the remaining suspension and continue mixing overnight at room temperature. 7. Weigh 8 g mannitol into a flask and add 80 mL RO water. Mix until complete dissolution is observed and store at room temperature. This will be used for resuspension after centrifugation if samples need to be lyophilized. 8. Collect the suspension after 24 hours and pour into 50 mL centrifuge tubes. Centrifuge the samples at a speed of 8,000 rpm for 20 minutes at 5°C. Decant the supernatant and resuspend one half the sample in 75 mL of filtered reverse osmosis (RO) water and the other half in 75 mL of 0.5% cetyl trimethylammonium bromide (CTAB) surfactant. 9. Centrifuge the samples again at a speed of 8,000 rpm for 20 minutes at 5°C and resuspend each of the pellets with a total of 20 mL mannitol solution. 10. After the second resuspension, measure the size of the particles using the Zetasizer (Table 1) . 11. Use suitable vials to transfer the remaining suspension and place them into the lyophilizer. 12. Measure the concentration of the samples using HPLC.
NanoART Morphology
1. Take nanoART suspension and briefly sonicate at 20% amplitude for 5 seconds with a sonication probe. Transfer 10 μL of the suspension into 1.5 mL of RO water within a 1.7 mL microcentrifuge tube and vortex for 10 seconds. 2. Take a 50 μL sample of the water-nanoART solution and transfer to a filtration apparatus consisting of a Swinnex 13 polypropylene filter holder assembled with a 0.2 μm polycarbonate filtration membrane (Nuclepore Track-Etched). The filtration apparatus is primed with 50 μL 0.2μm filtered distilled water prior to the addition of the diluted drug suspension. Vacuum is then applied to the apparatus until the entire solution volume has been completely pulled past the filtration membrane. 3. Once the membrane is dry, it is affixed to an aluminum pin stub using double stick conductive carbon tape and sputter coated with palladium.
The specimen stub is then imaged using, in our case, a JEOL JSM6300F low voltage, field emission scanning electron microscope ( Figure  2 ).
NanoART Visualization
1. Take the prepared nanoART suspensions and sonicate them for 10 seconds at 20% amplitude with a sonication probe. 2. Take a microscope slide cover slip and place it on an inverted microscope. On the cover slip mix 15 μL of the nanoART suspension with 100 μL of phosphate buffered saline (PBS) and mix by pipetting up and down several times. Visualize the nanoparticles using a 20x objective (Figure 3) .
Biology of nanoART

Isolation and Preparation of Blood Borne Monocyte and Monocyte-derived Macrophages (MDM)
1. Obtain human monocytes by leukapheresis from HIV-1 and hepatitis seronegative donors and purify the cells by counter-current centrifugal elutriation. Assess cell purity by immunolabeling with anti-CD68 (clone KP-1) from Wright-stained cytospins 1. 2. Culture purified monocytes in DMEM supplemented with 10% heat-inactivated pooled human serum, 1% glutamine, 50 μg/ mL gentamicin, 10 μg/ mL ciprofloxacin and 1000 U/ mL recombinant human macrophage colony stimulating factor (MCSF) at a concentration of 1x10 6 cells/ mL at 37°C in a humidified atmosphere with 5% CO 2 . Plate 2x10 6 cells per well in 6-well plates and culture cells for 7 days in order to allow monocytes to differentiate into macrophages 1. (Figure 3A) 7. Cell Uptake and Collection Table displays 
Discussion
NanoART are designed to improve HIV-1 therapeutics. We have proposed a monocyte-macrophage based drug delivery system as a first step to develop such technologies for clinical use and as a laboratory testing system for nanoformulated drug development. Our past works have shown that the system is viable for such an application 5, 6 .
In the current report, we have illustrated methods for synthesizing NP of commonly used HIV-1 medications (indinavir, IDV; ritonovir, RTV; efavirenz, EFV and atazanavir, ATV). This was achieved by wet milling, homogenization and ultrasonication. Importantly, our approach allows for modifications of nanoART physical characteristics such as size, shape and charge 5, 6 . By careful selection of surfactants, one can control the charge of the particle from highly negative to neutral to highly positive. By altering the processing time and intensity, one can control the size and render particles as small as ≤ 200 nm or as large as ≥ 3 μm. The shape of the particle can also be controlled, but to a lesser extent than the other physical characteristics. For example, spherical particles can be made via sonication with polymers while multi-sided geometric shapes can be produced via wet milling or homogenization. Wet milling and homogenization produce differently shaped particles, but this process is dependent on the fractionation method and cannot be directly controlled for. These properties of the manufacturing methods can enable researches to easily produce nanoART to exact design specifications. This is vitally important since the physicochemical properties of nanoART have a powerful effect upon both their stability and how they interact with cells. For example, we have shown that nanoART that are approximately 1 μm in size, have a strong positive charge, and have a multisided geometric shape are more rapidly taken up by macrophages, more stable once inside the cells, and released over a longer period of time 6.
A method for testing nanoART was developed that allows for simple screening of the particles' ability to be taken up, retained, and released by macrophages, one of the principle target cells of HIV-1, in addition to their capacity to inhibit viral replication. This allows one to easily differentiate nanoART based on performance and identify those that have the best chance of succeeding in an in vivo model, thus, increasing both the efficiency and speed of developing nanoART for human use.
It has been shown that mouse bone marrow macrophages when loaded ex vivo with nanoART and adoptively transferred by intravenous injection into humanized HIV-1 infected mice can travel to sites of active infection, including the central nervous system, and release drugs for up to 2 weeks to inhibit viral replication [2] [3] [4] . In addition, these nanoART loaded cells were also able to effectively reduce the numbers of virusinfected cells in plasma, lymph nodes, spleen, liver and lung as well as protect CD4+ cells 2 . These studies, although preliminary, demonstrate that a cell-mediated nanoART delivery system can distribute clinically significant amounts of drug to both blood and infected tissues. Because of the encouraging preliminary results from HIV-1 infected mouse studies, we are currently developing a simian immuno deficiency virus infected macaque model to further test the potential of nanoART for clinical use.
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